Publications by authors named "Jason Romancik"

Claim this Profile
O
Outcomes for CART as 2L vs 3L vs 4L or Beyond in Aggressive B-cell Lymphoma: Real World Evidence from the ABC Consortium.
John Seng Wang, Brandon Lee Ellsworth, Megan Melody, Narendranath Epperla, Deborah M Stephens, Jason T Romancik

Blood Adv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of tafasitamab and lenalidomide in large B-cell lymphoma based on prior CD19-directed CAR T exposure.
Mwanasha H Merrill, Robert A Redd, Nicholas Lambert, Paolo F Caimi, Priyanka Pullarkat, Jason Romancik

Hemasphere· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of Bispecific Antibodies After CAR T-Cell Failure for Large B-cell Lymphoma- Results from the ABC Consortium.
Megan Melody, Natalie S Grover, Stephanie Franco, Jason T Romancik, Matthew J Cortese

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subsets of follicular lymphoma 3B have divergent outcomes: results from the prospective multicenter MER and LEO cohorts.
Patrizia Mondello, Brianna Negaard, Andrew L Feldman, Brian K Link, Carla Casulo, Jason Romancik

Blood Cancer J· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autologous Transplant or CAR-T as Consolidation Options in MYC Rearranged Large B-Cell Lymphoma Patients in Remission After Salvage Treatments.
Fateeha Furqan, Kwang W Ahn, Manmeet Kaur, Jinalben Patel, Stephen Ansell, Jason Romancik

Am J Hematol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real World Outcomes of Patients with Aggressive Lymphoma and Autoimmune Disease Treated with CART.
Nicole J Altomare, Megan M Herr, Nisha M Nair, Deborah M Stephens, Jonathon B Cohen, Jason Romancik

Cancers (Basel)· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centers.
Viktoriya Zelikson, Ashwath Gurumurthi, Yazeed Sawalha, Kaitlin Annunzio, Aditi Saha, Jason Romancik

Haematologica· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy.
Reem Karmali, Geoffrey Shouse, Pallawi Torka, Tamara K Moyo, Jason Romancik

Blood Cancer J· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Development and Application of Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma.
Laura Sun, Jason T Romancik

J Pers Med· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the impact of laboratory-based eligibility criteria by race/ethnicity in first-line clinical trials of DLBCL.
Arushi Khurana, Raphael Mwangi, Loretta J Nastoupil, Patrick M Reagan, Umar Farooq, Jason T Romancik

Blood Adv· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy.
Megan Melody, Narendranath Epperla, Geoffrey Shouse, Jason Romancik, Pamela Allen

Blood Adv· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy.
Reem Karmali, Rushad Machhi, Narendranath Epperla, Geoffrey Shouse, Jason Romancik

Blood Adv· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy.
Jennifer L Crombie, Caron A Jacobson, Robert Redd, Geoffrey Shouse, Alex F Herrera, Jason Romancik

Haematologica· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study.
David A Qualls, Nicholas Lambert, Paolo F Caimi, Mwanasha Merrill, Priyanka Pullarkat, Jason Romancik

Blood· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study.
Narendranath Epperla, Lei Feng, Nirav N Shah, Lindsey Fitzgerald, Harsh Shah, Jason T Romancik

J Hematol Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions.
Ajay Major, Jovian Yu, Navika Shukla, Yan Che, Theodore G Karrison, Jason T Romancik

Blood Adv· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma.
Yazeed Sawalha, Subir Goyal, Jeffrey M Switchenko, Jason T Romancik, Manali Kamdar

Blood Adv· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL.
Joanna Zurko, Imran Nizamuddin, Narendranath Epperla, Kevin David, Jonathon B Cohen, Jason Romancik

Blood Adv· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixazomib With or Without Rituximab Following Maintenance Autologous Stem Cell Transplant in Mantle Cell Lymphoma: A Single-Center Phase I Trial.
Jason T Romancik, Zhengjia Chen, Pamela B Allen, Edmund K Waller, Kelly Valla

Clin Lymphoma Myeloma Leuk· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody binding and neutralization of live SARS-CoV-2 variants including BA.4/5 following booster vaccination of patients with B-cell malignancies.
Andres Chang, Akil Akhtar, Lilin Lai, Victor M Orellana-Noia, Susanne L Linderman, Jason T Romancik

Cancer Res Commun· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SOHO State of the Art Updates and Next Questions: Managing Relapsed Mantle Cell Lymphoma.
Jason T Romancik, Drew G Gerber, Tony Zhuang, Jonathon B Cohen

Clin Lymphoma Myeloma Leuk· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions.
Victor Manuel Orellana-Noia, Daniel R Reed, Ashley Alesia McCook, Jeremy Michael Sen, Christian M Barlow, Jason Romancik

Blood· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequencing of Novel Therapies for Mantle Cell Lymphoma.
Jason T Romancik, Jonathon B Cohen

Curr Treat Options Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma.
Reid W Merryman, Luca Castagna, Laura Giordano, Vincent T Ho, Paolo Corradini, Jason T Romancik

Leukemia· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma.
Reid W Merryman, Robert A Redd, Taiga Nishihori, Julio Chavez, Yago Nieto, Jason Romancik

Blood Adv· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis